top
 
More Languages
     
Latest News
View All


  
 

 
 
 
 
 
 
 

BSGI / Breast Specific Gamma Imaging

Dilon brochure

Performed with the Dilon 6800 Gamma Camera, Breast-Specific Gamma Imaging (BSGI) - sometimes called Molecular Breast Imaging - is an excellent problem-solving tool for questionable findings on mammography or breast ultrasound. It can also be helpful for evaluating areas of palpable concern when the mammogram and ultrasound are normal.

This molecular imaging technique has a high sensitivity for the early detection of breast cancer with infrequent false-positive results. Because the interpretation of BSGI is not affected by breast tissue density, it is an ideal diagnostic complement to mammography.

Medicare and most private insurance companies cover BSGI under standard nuclear breast imaging codes.

In May 2007, Weinstein Imaging Associates became the first facility in western Pennsylvania and the entire Pittsburgh tri-state region to offer this service.

 Please contact us with any questions.



Dilon brochure Dilon brochure Dilon brochure
Click on images to view the rest of
the Dilon brochure on BSGI
 

 


 About Dilon Technologies

Dilon Technologies Inc. is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, compact gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Technologies please visit www.dilon.com.

 Comparison of Breast Imaging Modalities

 
Mammography
Ultrasound
MRI
BSGI
Normal Breast        
Sensitivity
High
Variable
High
High
Specificity
Low
Medium
Variable
High
Dense Breast        
Sensitivity
Medium
Variable
High
High
Specificity
Low
Medium
Variable
High

Key: Low - less than 40%, Medium - 40 to 80%, High - greater than 80%, Variable - referenced range varies by more than 30%.

© Copyright 2007 Dilon Technologies

Benefit to Radiation Risk of Breast Specific Gamma Imaging Compared with Mammography in Screening Asymptomatic Women with Dense Breasts

Methodological aspects of 99m Tc sestamibi guided biopsy in breast cancer

Prosnostic value of primary tumor SUV on F-18 FDG PET/CT compared with semi-quantitative tumor uptake on Tc-99m sestamibi breast specific gamma imaging in invasive ductal breast cancer

Retrospective and comparative analysis of 99m Tc Sestamibi breast specific gamma imaging versus mammography, ultrasound and magnetic resonance imaging for the detection of breast cancer in Chinese women

Validity of breast specific gamma imaging for Breast Imaging Reporting and Data System 4 lesions on mammography and or ultrasuond

Breast Specific gamma imaging with Tc-99m sestamibi in the diagnosis of breast cancer and its semiquantitative index correlation with tumor biologic markers, subtypes and clinicopathologic characteristics

Breast-Specific Imaging for Detection of Mammographically Occult Breast Cancer in Women at Increased Risk

Relative Uptake Factor of Invasive Ductal Breast Cancer in Breast Specific Gamma Imaging as a Surrogate Parameter for Sub typing

Comparative Diagnostic Utility of Low-Dose Breast Specific Gamma Imaging to Current Clinical Standard

Visual and semi quantitative analyses of dual phase breast specific gamma imaging with Tc 99 m sestamibi in detecting primary breast cancer

Background parenchymal uptake on molecular breast imaging as a breast cancer risk factor  a case control study

Comparative Diagnostic Utility of Low Dose Breast Specific Gamma Imaging to Current Clinical Standard

Breast-Specific Gamma Imaging with Tc-Setamibi and MRI in the Diagnosis of Breast Cancer-A comparative Study

Image-Detected Breast Cancer:  State-of-the-Art Diagnosis and Treatment

Real-world application of BSGI, initial experience at a community breast center and its potential impact on clinical care.

Low-Dose Molecular Breast Imaging is possible but Clinicians Should Proceed Cautiously

A Protocol for Imaging Axillary Lymph Nodes in Patients undergoing Breast-Specific Imaging

Breast-specific gamma imaging as an adjunct modality for the diagnosis of invasive breast cancer with correlation to tumour size and grade

Detection of Occult Foci of Breast Cancer Using Breast-Specific Gamma Imaging in women with One Mammographic or Clinically Suspicious breast Lesion

BSGI/MBI is Gaining Momentum as a Standard of Care in the Diagnostic Workup of Patients

Breast Scintigraphy Bibliography:  A Literary History from Scintimammography to Breast-Specific Gamma Imaging (BSGI)

BSGI exhbits at the RSNA 2010

New Jersey Medical Facility Introduces Newest Technique to Identify Cancerous Breast Lesions

New Study Points to Important Information Regarding Radiation Dose of BSGI/MBI

BSGI May outperform Breast ultrasound for Evaluating Patients with Indeterminate Mammograms

New study points to important information regading radiation dose of BSGI/MBI

Molecular Breast Imaging may be Useful in PASH diagnosis

New Study offers more Information on the radiation dose from BSGI

Radiation Risk in Perspective

BSGI Comparable to MRI in Detecting Additional Occult Breast Cancer Lesion in Certain Women.

Breast Scintigraphy Guidlines

The Clinical Impact of BSGI

Results of a Multi-Center Patient Registry to Determine the Clinical Impact of BSGI

BSGI makes Significant Impact on Detection of Breast Cancer in Patients with Negative Mammographic Findings


Medipattern Chosen by Doshi Diagnostic Imaging to Support Total Breast Care Program


BSGI Proves Highly Sensitive for the Detection of Ductal Carcinoma In Situ

GammaLoc cleared by FDA!


Molecular-based Breast Imaging:  Catching Up to Breast MRI

The Breast Journal article showing that BSGI and MRI have similar sensitivities, but BSGI has higher specificity than MRI.

Academic Radiology article showing that BSGI has better sensitivity than MRI or mammography for detecting ductal carcinoma in situ (DCIS).

Our press release about BSGI, which includes photos and video clips of this new test.

Various media articles about
our role in introducing BSGI to the Pittsburgh region.

April 2008 article showing that BSGI found breast cancer in 2% of women with normal mammograms.

Radio ad on KDKA-AM featuring BSGI usage in our practice.

BSGI May Reduce Unnecesary Biopsies

Building a Case for BSGI 

 

 

 

 

 

 

     
 
Copyright 2004-17  Weinstein Imaging Associates, Pittsburgh, PA       North Hills 412-630-2649  •  Shadyside 412-441-1161  •  South Hills 412-440-6999
Home  |  About Us  |  Services  |  For Patients  |  For Doctors  |  News / Events  |  Links  |  FAQ  |  Contact Us